Sandoz study data shows effectiveness of AirFluSal Forspiro inhaler

Sandoz has announced the publication of new clinical data that demonstrates the treatment persistence benefits associated with its AirFluSal Forspiro respiratory inhaler.

Published in the Journal of Allergy and Clinical Immunology: In Practice, the study showed that rate of patient persistence using AirFluSal Forspiro was twice as high as for the original reference product.

Patients using the Sandoz device showed a persistence rate of 22.9 percent, compared to 10.5 percent for those using the reference product device. A total of 11,744 patients were included in a matched pair analysis for this research.

It is known that poor rates of persistence to treatment often result in poor outcomes, including disease exacerbations, reduced quality of life, hospitalisation, increased mortality, greater burden on the healthcare system and higher economic costs.

It is estimated that a large number of patients abandon their asthma treatment, meaning an inhaler that can reverse this trend could be of great benefit.

Dr Spencer Jones, head of global medical affairs for Sandoz's respiratory business, said: "These results fully validate our decision at Sandoz to develop our inhaler device in close collaboration with patients, incorporating their feedback."

With over 20 years of experience within the consumer market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current consumer roles we have available, you can search for the latest job roles, register your details, or contact the team today.